Skip to main content

Avadel Pharmaceuticals PLC (AVDL)

NASDAQ: AVDL · Delayed Price · USD
8.05
-0.17 (-2.07%)
After-hours:Oct 21, 2021 5:12 PM EDT
8.22
-0.22 (-2.55%)
At close: Oct 21, 4:00 PM
Market Cap488.40M
Revenue (ttm)n/a
Net Income (ttm)-56.01M
Shares Out58.60M
EPS (ttm)-1.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume995,808
Open8.46
Previous Close8.44
Day's Range8.03 - 8.49
52-Week Range4.95 - 10.80
Beta1.17
AnalystsStrong Buy
Price Target17.75 (+115.9%)
Est. Earnings DateNov 8, 2021

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

IndustryPharmaceuticals
IPO DateJun 7, 1996
CEOGregory Divis
Employees32
Stock ExchangeNASDAQ
Ticker SymbolAVDL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price forecast is 17.75, which is an increase of 115.94% from the latest price.

Price Target
$17.75
(115.94% upside)
Analyst Consensus: Strong Buy

News

Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosin...

- Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency compare...

2 days ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDL

New York, New York--(Newsfile Corp. - October 18, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc ("Avadel" or the "Company") (NASDAQ: AVDL). Such inv...

2 days ago - Newsfile Corp

Why Shares of Avadel Are Sinking Today

A key regulatory decision is overdue, leaving shareholders to wonder when it might arrive.

3 days ago - The Motley Fool

Avadel Shares Fall As FDA Pushes Approval For Its Narcolepsy Treatment Candidate

The FDA has notified Avadel Pharmaceuticals plc (NASDAQ: AVDL) that the review of its marketing application for FT218 is still ongoing, and action will likely not be taken in October.  Related:   Needha...

3 days ago - Benzinga

Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy

DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and Drug ...

6 days ago - GlobeNewsWire

Implied Volatility Surging for Avadel (AVDL) Stock Options

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narco...

DUBLIN, Ireland, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

2 months ago - GlobeNewsWire

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results

DUBLIN, Ireland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

2 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th

DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium oxyb...

2 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021

DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

3 months ago - GlobeNewsWire

Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients...

DUBLIN, Ireland, June 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

4 months ago - GlobeNewsWire

Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021

DUBLIN, Ireland, June 03, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

4 months ago - GlobeNewsWire

Avadel Pharmaceuticals Expands Leadership Team with Three Strategic Hires

Bolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly FT218 for narcolepsy Bolsters team with addition...

4 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tre...

4 months ago - GlobeNewsWire

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results

DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designe...

5 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate desig...

5 months ago - GlobeNewsWire

Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 Am...

DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-S...

6 months ago - GlobeNewsWire

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the T...

FT218 assigned PDUFA target action date of October 15, 2021 FT218 assigned PDUFA target action date of October 15, 2021

7 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on...

DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate design...

7 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

8 months ago - GlobeNewsWire

3 Fast-Growing Small Caps to Consider

Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year basis.

Other symbols:ADUSIRS
10 months ago - GuruFocus

Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs

DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate design...

10 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

10 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for tr...

11 months ago - GlobeNewsWire

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q3 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha